PODD · Insulet Corporation
$163.26
+1.50% last session
End-of-day data · updated 2026-07-28
Market cap
$11B
Enterprise value
$12B
Trailing P/E
38.6
Forward P/E
20.5
Dividend yield
—
Beta
1.11
Avg volume
2M
Employees
5K
2D change
—
5D change
4.18%
10D change
0.57%
30D change
4.27%
60D change
13.84%
MTD change
3.26%
YTD change
-41.95%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PODD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-13
Latest call per bank · past 12 months
RBC Capital
Outperform$245
+50.1% vs priceCitigroup
Neutral$172
+5.4% vs priceDeutsche Bank
Buy$190
+16.4% vs priceBank of America
Buy$208
+27.4% vs priceBarclays
Underweight$198
+21.3% vs priceJP Morgan
Overweight$275
+68.4% vs priceWells Fargo
Overweight$255
+56.2% vs priceGoldman Sachs
Buy$277
+69.7% vs priceUBS
Buy$400
+145.0% vs priceJefferies
Buy$400
+145.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | Truist Securities | Maintains | Buy | $219 → $210 |
| 2026-07-13 | RBC Capital | Maintains | Outperform | $280 → $245 |
| 2026-07-10 | Stifel | Maintains | Buy | $250 → $225 |
| 2026-07-08 | Citigroup | Maintains | Neutral | $165 → $172 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $200 → $180 |
| 2026-06-23 | Deutsche Bank | Initiates | Buy | $0.00 → $190 |
| 2026-06-12 | Truist Securities | Maintains | Buy | $250 → $219 |
| 2026-05-28 | Citigroup | Maintains | Neutral | $175 → $165 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.7% above the 50-day MA ($154.09).
- Price vs 200-day MA: Trading 28.8% below the 200-day MA ($235.15).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.36) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($138.97) and high ($352.82).
PODD Price Chart
Loading chart for PODD…
Fundamentals
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
More in Medical Devices
ABT
Abbott Laboratories
$182B -15.0% YTD
SYK
Stryker Corporation
$129B -3.7% YTD
MDT
Medtronic plc.
$108B -10.8% YTD
BSX
Boston Scientific Corporation
$68B -52.3% YTD
EW
Edwards Lifesciences Corporatio
$48B -2.6% YTD
GEHC
GE HealthCare Technologies Inc.
$28B -25.4% YTD
DXCM
DexCom, Inc.
$28B 10.5% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.